Interferon-α2b instillation prophylaxis in superficial bladder cancer—a prospective, controlled three-armed trial

Engelmann, U.; Knopf, H.-J.; Graff, J.

doi:10.1097/00001813-199205000-00008

Cited by 20 publications

(8 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Engelmann et aI. suggested that a combination of interferon and mitomycin C was more effective than either drug alone [8]. and the present trial with 50 mg epirubicin combined with low-dose alpha 2b-IFN similarly argues in favour of combined therapy, as the number of patients having recurrences, the number of recurrent tumours and the recurrence rate were all reduced.…”

Section: Discussionsupporting

confidence: 48%

“…The most common approach to treating superficial bladder cancer is transurethral resection (TUR) with fulguration of the tumour, but even with this treatment up to 85% of patients will have recurrent tumours, often during the first year [1][2][3]. Intravesical chemotherapy has therefore been investigated widely and used as a prophylactic against recurrences [4][5][6]: since 1976, immunotherapy has also offered substantial possibilities for treating superficial bladder cancer [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

“…Intravesical immunotherapy with alpha2b-interferon (alpha2b-IFN) has been shown to be of comparable efficacy to conventional chemotherapy, with a low incidence of systemic or local adverse effects [7]. Interferon has also been used succesfully in combination with chemotherapeutic drugs such as mitomycin C and epirubicin [8,12]. Although the Accepted for publication 22 August 1995 © 1995 British Journal of Urology rate were calculated to assess the behaviour of the disease.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A controlled study of intravesical epirubicin with or without alpha2b‐interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder

Raitanen

Lukkarinen

1995

British Journal of Urology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 48%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A controlled study of intravesical epirubicin with or without alpha2b‐interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder

Raitanen

Lukkarinen

1995

British Journal of Urology

View full text Add to dashboard Cite

show abstract

“…The immunomodulator ABPP (2-amino-5-iodo-6-phenyl-4-pyrimidine), which acts as an IFN inducer, has in fact been shown to enhance the activity of BCG against the murine bladder tumor MBT-2 [75]. Preliminary results of a study combining IFN-a and mitomycin C for superficial bladder cancer suggest that the combination may be more effective than either agent alone [76],…”

Section: Bladder Cancermentioning

confidence: 99%

Interferons in the Therapy of Solid Tumors

Agarwala

Kirkwood

1994

Oncology

View full text Add to dashboard Cite

Interferons, a group of naturally occurring proteins, possess potent immunological effects. The availability of large amounts of purified interferon through recombinant DNA technology has led to the testing of these agents against a number of tumor types. Interferon-α has been the most widely studied. The most encouraging results have been observed in the treatment of melanoma among nonhematological neoplasms, and in the locoregional treatment of other tumor types. It is hoped that further research into the use of the interferons, both singly and in combination with chemotherapy and other immunological agents, will lead to a better elucidation of their therapeutic role against cancer. In this article, the use of interferons in the treatment of solid tumors is reviewed.

show abstract

“…Introna@ and cytotoxic agents administered together in the treatment of both gastric cancer and colorectal cancer have synergistic effects, with a higher respons rate compared with monotherapy with cytotoxic agents (8, 19). Combination of IntronaB and various cytotoxic agents has also been proposed to increase the response rate and decrease the recurrence rate in patients with superficial bladder tumour (3,4).…”

mentioning

confidence: 99%

Effects of Intravesical Instillation of 5-Fluorouracil and Interferon in Patients with Recurrent Superficial Urinary Bladder Carcinoma: A Clinical and Pharmacodynamic Study

Hugosson¹,

Bergdahl²,

Carlsson³

et al. 1997

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

Eleven patients with recurrent superficial bladder tumours were treated with 6 weekly instillations of 10 million IU Introna and 1000 mg 5-fluorouracil for 1 h. Before and immediately after the first treatment biopsies were taken from normal urothelium and tumour for analysis of thymidylate synthase (TS). One papillary tumour was left as a marker. Tumour tissue had 9 times higher TS concentrations than normal urothelium (0.97 versus 0.11 pmol/g, p < 0.005). Despite a large variation in TS concentration in the tumours between different patients (range 0.02-2.24 pmol/g), after instillation the TS concentration decreased significantly in all but one patient. Six patients had complete and 2 had partial tumour regression after treatment. The effect was inversely correlated to the initial TS value. A low TS value seemed to predict a good response. The data suggest that weekly administrations are not sufficient in those with high TS concentrations. New treatment schedules may be beneficial in those with highly proliferating bladder tumours.

show abstract

Interferon-α2b instillation prophylaxis in superficial bladder cancer—a prospective, controlled three-armed trial

Cited by 20 publications

References 1 publication

A controlled study of intravesical epirubicin with or without alpha2b‐interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder

A controlled study of intravesical epirubicin with or without alpha2b‐interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder

Interferons in the Therapy of Solid Tumors

Effects of Intravesical Instillation of 5-Fluorouracil and Interferon in Patients with Recurrent Superficial Urinary Bladder Carcinoma: A Clinical and Pharmacodynamic Study

Contact Info

Product

Resources

About